Accuray Incorporated has signed an agreement with the Apollo Hospitals Group in Chennai and New Delhi, India, for the acquisition of two Radixact Systems, radiation therapy devices that have been proven to deliver highly accurate treatments for a broad range of tumors anywhere in the body.
The installation of these systems, one replacing a conventional linear accelerator and the other in a new vault, will expand access to state-of-the-art cancer treatment technology for the people of India. The orders were entered into backlog during Accuray Incorporated’s Q3 fiscal quarter, which ends March 31, 2018.
Apollo Hospitals was established in 1983 and has since emerged as Asia's foremost integrated healthcare services provider. This patient-centric organization's mission is to bring the highest standards of healthcare to every patient.
“For over 25 years, Apollo Cancer Centres have been serving patients from over 140 countries. Our fine teams of oncologists persevere relentlessly to offer patients the global best in cancer care and a contemporary product such as the Radixact System will help our patients by minimizing the impact on their quality of life,” said Dr. Prathap C. Reddy, Chairman, Apollo Hospitals Group.
Radixact System Benefits
“The Radixact System can be used to treat virtually any tumor type including breast, head and neck, lung and prostate cancers, during every stage of the treatment journey, from primary cases, to recurrent and metastatic diseases,” said Lionel Hadjadjeba, M.D., senior vice president, and chief commercial officer at Accuray. This gives the Apollo Hospitals clinical team tremendous flexibility and enables them to tailor treatments to the specific needs of each patient.”
Back To Top
India's Apollo Hospitals acquire two Accuray Radixact Systems. Appl Rad Oncol.